keyword
https://read.qxmd.com/read/38456584/consensus-statement-on-the-diagnosis-and-treatment-of-sclerosing-diseases-of-the-skin-part-1-localized-scleroderma-systemic-sclerosis-and-overlap-syndromes
#21
JOURNAL ARTICLE
R Knobler, M Geroldinger-Simić, A Kreuter, N Hunzelmann, P Moinzadeh, F Rongioletti, C P Denton, L Mouthon, M Cutolo, V Smith, A Gabrielli, M Bagot, A B Olesen, I Foeldvari, A Jalili, V Kähäri, S Kárpáti, K Kofoed, M Olszewska, J Panelius, P Quaglino, J Seneschal, M Sticherling, C Sunderkötter, A Tanew, P Wolf, M Worm, A Skrok, L Rudnicka, T Krieg
The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis...
March 8, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/38452646/disparities-in-dmt-treatment-demographic-and-neurocognitive-differences-between-ms-patients-currently-treated-versus-not-treated-with-disease-modifying-therapies
#22
JOURNAL ARTICLE
Victoria M Leavitt, Jordan D Dworkin, Rachel Galioto, Alexander S Ratzan
BACKGROUND: Current treatment guidelines recommend consideration of disease-modifying therapy (DMT) for all multiple sclerosis (MS) patients, but barriers to access have begun to be identified. In particular, prior studies have found that people with higher education have better access to DMTs, perhaps explained by the association of higher education with higher income. And while the majority of people with MS are women, being male is also associated with higher income. These factors argue for the need to better understand whether there are differences in DMT uptake based on sex and education...
February 22, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38432589/perspective-the-impact-of-fasting-and-caloric-restriction-on-neurodegenerative-diseases-in-humans
#23
JOURNAL ARTICLE
Bérénice Hansen, Kirsten Roomp, Hebah Ebid, Jochen G Schneider
Neurodegenerative diseases (NDs) are characterized by the progressive functional and structural denaturation of neurons in the central and peripheral nervous systems. Despite the wide range of genetic predispositions, the increased emergence of these disorders has been associated with a variety of modifiable risk factors, including lifestyle factors. Diet has been shown to influence cognitive alterations in the elderly population with age-related brain pathologies, and specific dietary interventions might, therefore, confer preservatory protection to neural structures...
March 1, 2024: Advances in Nutrition
https://read.qxmd.com/read/38426689/s2k-guideline-diagnosis-and-therapy-of-localized-scleroderma
#24
JOURNAL ARTICLE
Alexander Kreuter, Pia Moinzadeh, Maria Kinberger, Gerd Horneff, Margitta Worm, Ricardo N Werner, Andreas Hammacher, Thomas Krieg, Jörg Wenzel, Michael Oeschger, Lisa Weibel, Robert Müllegger, Nicolas Hunzelmann
The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sclerotic skin diseases in which, depending on the subtype and localisation, structures such as adipose tissue, muscles, joints, and bones may also be affected. Involvement of internal organs or progression to systemic sclerosis does not occur. LoS can be classified into four main forms: limited, generalized, linear, and mixed forms, with some additional subtypes. For cases of limited skin involvement, the guideline primarily recommends therapy with topical corticosteroids...
March 1, 2024: Journal der Deutschen Dermatologischen Gesellschaft: JDDG
https://read.qxmd.com/read/38420750/grading-system-for-assessing-the-confidence-in-the-epileptogenic-zone-reported-in-published-studies-a-delphi-consensus-study
#25
JOURNAL ARTICLE
Philippe Ryvlin, Carmen Barba, Fabrice Bartolomei, Christoph Baumgartner, Milan Brazdil, Daniel Fabo, Firas Fahoum, Birgit Frauscher, Akio Ikeda, Samden Lhatoo, Jayanti Mani, Aileen McGonigal, Eeva-Liisa Metsahonkala, Ioana Mindruta, Dang Khoa Nguyen, Sylvain Rheims, Rodrigo Rocamora, Bertil Rydenhag, Stephan Schuele, Andreas Schulze-Bonhage, Rainer Surges, Serge Vulliemoz, Sandor Beniczky
OBJECTIVE: This study was undertaken to develop a standardized grading system based on expert consensus for evaluating the level of confidence in the localization of the epileptogenic zone (EZ) as reported in published studies, to harmonize and facilitate systematic reviews in the field of epilepsy surgery. METHODS: We conducted a Delphi study involving 22 experts from 18 countries, who were asked to rate their level of confidence in the localization of the EZ for various theoretical clinical scenarios, using different scales...
February 29, 2024: Epilepsia
https://read.qxmd.com/read/38403972/amp-activated-protein-kinase-as-a-mediator-of-mitochondrial-dysfunction-of-multiple-sclerosis-in-animal-models-a-systematic-review
#26
REVIEW
Hamid Askari, Fatemeh Rabiei, Fatemeh Lohrasbi, Sara Ghadir, Ahmad Mehdipour Arbastan, Maryam Ghasemi-Kasman
Multiple sclerosis (MS) is a chronic central nervous system (CNS) disorder characterized by demyelination, neuronal damage, and oligodendrocyte depletion. Reliable biomarkers are essential for early diagnosis and disease management. Emerging research highlights the role of mitochondrial dysfunction and oxidative stress in CNS disorders, including MS, in which mitochondria are central to the degenerative process. Adenosine monophosphate-activated protein kinase (AMPK) regulates the mitochondrial energy balance and initiates responses in neurodegenerative conditions...
February 25, 2024: Journal of Cellular Physiology
https://read.qxmd.com/read/38378970/treatment-of-pulmonary-arterial-hypertension-in-patients-with-connective-tissue-diseases-a-systematic-review-and-meta-analysis
#27
JOURNAL ARTICLE
Mustafa Erdogan, Sinem Nihal Esatoglu, Burcak Kilickiran Avci, Gulen Hatemi
The evidence for the treatment of connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) mostly depends on subgroup or post hoc analysis of randomized controlled trials (RCTs). Thus, we performed a meta-analysis of RCTs that reported outcomes for CTD-PAH. PubMed and EMBASE were searched for CTD-PAH treatment. The selected outcomes were functional class (FC) change, survival rates, 6-min walk distance (6-MWD), clinical worsening (CW), N-terminal prohormone BNP (NT-proBNP), pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), right atrial pressure (RAP), and cardiac index (CI)...
February 20, 2024: Internal and Emergency Medicine
https://read.qxmd.com/read/38366285/sphingosine-1-phosphate-receptor-modulators-in-multiple-sclerosis-treatment-a-practical-review
#28
REVIEW
Patricia K Coyle, Mark S Freedman, Bruce A Cohen, Bruce A C Cree, Clyde E Markowitz
Four sphingosine 1-phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head-to-head clinical studies were conducted, direct efficacy comparisons cannot be made...
February 16, 2024: Annals of Clinical and Translational Neurology
https://read.qxmd.com/read/38338724/how-to-use-the-cuprizone-model-to-study-de-and-remyelination
#29
REVIEW
Markus Kipp
Multiple sclerosis (MS) is an autoimmune and inflammatory disorder affecting the central nervous system whose cause is still largely unknown. Oligodendrocyte degeneration results in demyelination of axons, which can eventually be repaired by a mechanism called remyelination. Prevention of demyelination and the pharmacological support of remyelination are two promising strategies to ameliorate disease progression in MS patients. The cuprizone model is commonly employed to investigate oligodendrocyte degeneration mechanisms or to explore remyelination pathways...
January 24, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38333530/use-of-exercise-tests-in-screening-for-pulmonary-arterial-hypertension-in-systemic-sclerosis-a-systematic-literature-review
#30
JOURNAL ARTICLE
Sarah Madigan, Susanna Proudman, David Schembri, Huw Davies, Robert Adams
BACKGROUND AND OBJECTIVE: Patients with systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH) have a poor prognosis, accounting for 30% of all SSc-related deaths. Guidelines recommend annual screening for PAH regardless of symptoms, as early treatment improves outcomes. Current protocols include combinations of clinical features, biomarkers, pulmonary function tests, and echocardiography. None include exercise testing, although early-stage PAH may only be evident during exercise...
February 2024: Journal of Scleroderma and related Disorders
https://read.qxmd.com/read/38333520/approval-status-of-essential-therapeutic-drugs-for-systemic-sclerosis-versus-that-of-drugs-for-rheumatoid-arthritis
#31
JOURNAL ARTICLE
Ki Won Moon, Soo-Hee Hwang, Jieun Yun, Eun Bong Lee
OBJECTIVE: Systemic sclerosis, a rare disease characterized by chronic multisystem fibrosis, requires lifelong management, necessitating enough insurance coverage for the patient. Official drug approval is the first step to ensuring that the drug is covered by insurance. In this study, we investigated the approval status of essential therapeutic drugs for systemic sclerosis across eight countries and compared it with that of drugs for rheumatoid arthritis. METHODS: The essential therapeutic drug lists for systemic sclerosis and rheumatoid arthritis were taken from the guidelines of the American College of Rheumatology and the European Alliance of Associations for Rheumatology...
February 2024: Journal of Scleroderma and related Disorders
https://read.qxmd.com/read/38301324/examining-dietary-habits-in-the-context-of-multiple-sclerosis-a-comprehensive-investigative-approach
#32
JOURNAL ARTICLE
Büşra Atabilen, Yasemin Akdevelioğlu, Pınar Acar Özen, Aslı Tuncer
AIMS: The aim of this study is to evaluate the nutritional status of patients with multiple sclerosis (MS) and to develop suggestions for changing eating habits in a healthy direction. METHODS: The study was conducted on 171 participants (80.1 % female; 19.9 % male) diagnosed with MS between the ages of 18-60 who applied to Ankara Hacettepe University Hospital Neurology Outpatient Clinic between June 2021 and March 2023. Body weight, height, body composition, waist circumference, upper mid-arm circumference and hand grip strength were measured in accordance with the technique of anthropometric measurements...
March 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38288970/fungicides-as-a-risk-factor-for-the-development-of-neurological-diseases-and-disorders-in-humans-a-systematic-review
#33
REVIEW
Renata Sano Lini, Deborah Thais Palma Scanferla, Nadya Garcia de Oliveira, Raul Gomes Aguera, Thais da Silva Santos, Jorge Juarez Vieira Teixeira, Alice Maria de Souza Kaneshima, Simone Aparecida Galerani Mossini
Although studies show that pesticides, especially insecticides, may be toxic to humans, publications on the neurological effects of fungicides are scarce. As fungicides are used widely in Brazil, it is necessary to gather evidence to support actions aimed at safely using of these chemicals. We investigated through a systematic review of publications on the use of fungicides and consequences of exposure related to nervous system diseases or neurological disorders in humans. The protocol review was registered on PROSPERO and followed the guidelines of the PRISMA-Statement...
January 30, 2024: Critical Reviews in Toxicology
https://read.qxmd.com/read/38245998/consensus-recommendations-for-diagnosis-and-treatment-of-multiple-sclerosis-2023-revision-of-the-menactrims-guidelines
#34
REVIEW
B Yamout, M Al-Jumah, M A Sahraian, Y Almalik, J Al Khaburi, N Shalaby, S Aljarallah, S Bohlega, M Dahdaleh, A Almahdawi, S J Khoury, S Koussa, E Slassi, S Daoudi, H Aref, S Mrabet, M Zeineddine, M Zakaria, J Inshasi, R Gouider, R Alroughani
With evolving diagnostic criteria and the advent of new oral and parenteral therapies for Multiple Sclerosis (MS), most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination in space and time and exclude alternative diseases that can explain the findings at hand. The differential diagnostic workup should be guided by clinical and laboratory red flags to avoid unnecessary tests. Appropriate selection of MS therapies is critical to maximize patient benefit...
March 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38224991/contribution-of-left-ventricular-diastolic-dysfunction-to-survival-and-breathlessness-in-systemic-sclerosis-interstitial-lung-disease
#35
JOURNAL ARTICLE
Jessica L Fairley, Dylan Hansen, Andrew Burns, David Prior, André La Gerche, Kathleen Morrisroe, Wendy Stevens, Mandana Nikpour, Laura Ross
OBJECTIVE: To explore the impact of left ventricular diastolic dysfunction (LVDD) in systemic-sclerosis (SSc)-associated interstitial lung disease (ILD), and to investigate SSc-specific associations and clinical correlates of LVDD. METHODS: One-hundred and two Australian Scleroderma Cohort Study participants with definite SSc and radiographic ILD were included. Diastolic function was classified as normal, indeterminate, or abnormal according to 2016 ASE/EACVI guidelines for assessment of left ventricular diastolic function...
January 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38222726/immunological-outcomes-of-autologous-hematopoietic-stem-cell-transplantation-for-multiple-sclerosis-a-systematic-review
#36
REVIEW
Alla Sai Santhosha Mrudula, Naga L P Avula, Sanah Kauser Ahmed, Rishabh B Salian, Deekshitha Alla, Preethi Jagannath, Sri S S P Polasu, Pranathi Rudra, Yussif Issaka, Moksh S Khetan, Trisha Gupta
BACKGROUND: Autologous hematopoietic stem cell transplantation (AHSCT) is an extensive procedure that allows for the depletion of the immune system and its restoration from hemopoietic stem cells. The approach has been modified for the treatment of severe immune-mediated illnesses, including multiple sclerosis (MS), after being initially devised for the treatment of hematological malignancies. OBJECTIVE: This systematic review aims to determine and consolidate the information on the short-term and long-term immunological effects of AHSCT on the cellular level in MS patients...
January 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38220493/national-diagnostic-and-care-protocols-ndcp-for-hematopoietic-stem-cell-transplantation-in-autoimmune-diseases
#37
JOURNAL ARTICLE
D Farge, G Pugnet, M Allez, C Castilla-Llorente, E Chatelus, P Cintas, C Faucher-Barbey, P Labauge, C Labeyrie, B Lioure, A Maria, D Michonneau, M Puyade, M Talouarn, L Terriou, X Treton, G Wojtasik, H Zephir, Z Marjanovic
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and relapsing-remitting multiple sclerosis (MS) and available as part of routine care in accredited center. HSCT is also recommended, with varying levels of evidence, as an alternative treatment for several ADs, when refractory to conventional therapy, including specific cases of connective tissue diseases or vasculitis, inflammatory neurological diseases, and more rarely severe refractory Crohn's disease...
January 13, 2024: La Revue de Médecine Interne
https://read.qxmd.com/read/38198710/neuropsychiatric-manifestations-of-tuberous-sclerosis-and-management-options-a-narrative-review
#38
REVIEW
Parul Gupta, Mamidipalli Sai Spoorthy, Pooja R Raikar
Importance: Tuberous sclerosis is an autosomal dominant genetic disorder that affects multiple organ systems and causes a wide range of physical manifestations. It commonly involves the brain, skin, heart, eyes, kidneys, and lungs. Individuals mostly present with neuropsychiatric symptoms, comprising a noteworthy source of morbidity and mortality. Observation : Ninety percent of individuals with tuberous sclerosis have associated neuropsychiatric manifestations including attention-deficit/hyperactivity disorder, autism spectrum disorder, and intellectual disability, which are typically underidentified and undertreated...
January 4, 2024: Primary Care Companion to CNS Disorders
https://read.qxmd.com/read/38191065/childhood-mixed-connective-tissue-disease-at-disease-onset-evidence-from-a-systematic-review
#39
REVIEW
Alberto Terminiello, Edoardo Marrani, Ilaria Pagnini, Ilaria Maccora, Valerio Maniscalco, Sarah Abu Rumeileh, Maria Vincenza Mastrolia, Gabriele Simonini
OBJECTIVE: Childhood Mixed Connective Tissue Disease (cMCTD) is the rarest pediatric connective tissue disease that includes features of systemic lupus erythematosus, polymyositis/dermatomyositis, juvenile idiopathic arthritis, and systemic sclerosis, identified by Sharp in 1972 and whose diagnosis remains challenging. This systematic review aims to identify clinical features at the onset of cMCTD and manifestations not currently included into the available diagnostic criteria. METHODS: A systematic literature review was performed in accordance with PRISMA guidelines 2020 using bibliographic databases: MEDLINE via PubMed and EMBASE...
January 6, 2024: Autoimmunity Reviews
https://read.qxmd.com/read/38183694/utility-of-the-brief-assessment-of-cognitive-health-bach-computerized-screening-tool-in-identifying-ms-related-cognitive-impairment
#40
JOURNAL ARTICLE
Karlee S Patrick, Shinjon Chakrabati, Tasha Rhoads, Robyn M Busch, Darlene P Floden, Rachel Galioto
BACKGROUND: Current guidelines recommend that individuals with MS are screened annually for processing speed deficits, often using the Symbol Digit Modalities Test (SDMT). However, given the heterogeneity of cognitive deficits in individuals with MS, other screening measures that assess a range of cognitive domains are necessary. The current cross-sectional study aimed to examine the ability of the computerized, self-administered Brief Assessment of Cognitive Health (BACH) screening measure to detect the presence of cognitive impairment in adults with MS as determined by performance on a standard neuropsychological test battery...
December 22, 2023: Multiple Sclerosis and related Disorders
keyword
keyword
119699
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.